Gonadorelin
GnRH
Gonadorelin (GnRH) is a hormonal & sexual research compound. Synthetic GnRH — stimulates the pituitary to release LH/FSH, keeping the testicular axis active (the HCG alternative that works upstream).
Gonadorelin quick facts
| Reported research dose | 100mcg-200mcg |
| Route | Subq |
| Frequency | 1-2x Daily (or pulsatile) · Varies |
| Half-life | ~2-4 min |
| Forms | Injectable |
| Evidence level | Human (established) |
Short half-life means frequent/pulsatile dosing — that's the trade for staying more physiologic than HCG.
How Gonadorelin works
Synthetic GnRH — stimulates the pituitary to release LH/FSH, keeping the testicular axis active (the HCG alternative that works upstream).
Proposed benefits
Researched for libido, hormonal signaling and reproductive / sexual function.
Can you actually get Gonadorelin?
Compounded by prescription for fertility and PCT protocols. Needs a prescriber who will monitor the axis; I have no partner route.
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Gonadorelin
Graded by what exists behind each claim.
✅ Clinically validated
- Synthetic GnRH, used clinically as a diagnostic agent for pituitary function and historically in pulsatile pumps to induce fertility in hypogonadotropic hypogonadism — where it works well when delivered pulsatile.
📊 Correlative data
- Used in TRT practice as an hCG alternative for maintaining testicular function. The clinical evidence for that specific use is thin compared with hCG's, and the very short half-life makes practical dosing contentious.
🧪 Theoretical / extrapolated
- Identical to endogenous GnRH, acting on the pituitary to release LH and FSH. Half-life is 2–4 minutes.
- Pulsatility is everything here. Pulsatile GnRH stimulates the axis; continuous GnRH signaling *suppresses* it — which is precisely how the GnRH agonists used in prostate cancer work. Dosing frequency is not a detail, it determines the direction of the effect.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Gonadorelin actually does
Gonadorelin is the single clearest example in endocrinology of a molecule whose effect is set by its delivery pattern rather than by its dose. Given in pulses it switches the reproductive axis on. Given continuously, the identical molecule switches it off. Nothing else on this site has that property so completely, and it is the reason this page is written around timing rather than around milligrams.
The molecule. Gonadorelin is synthetic gonadotropin-releasing hormone: the natural mammalian decapeptide, sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2. Both ends are protected — a pyroglutamate at the N-terminus and an amide at the C-terminus — which is a common motif in hypothalamic releasing hormones and blocks the exopeptidases that would otherwise chew inward from either end. It is still cleared in minutes, and the card's 2 to 4 minutes is the number: endopeptidases cut the chain internally, most notably between the glycine and leucine residues in the middle, and no terminal protection prevents that.
Two to four minutes is not a flaw. It is the entire design. The hypothalamus releases GnRH into the hypophyseal portal circulation as discrete bursts roughly every 60 to 120 minutes. A signal that must be read as a pulse has to disappear between pulses, and a hormone with a two-minute half-life delivered into a short portal vessel does exactly that. A long-acting GnRH would destroy the information it carries.
What the receptor does with the pulse, and the strange thing about it. The GnRH receptor on the pituitary gonadotroph is a Gq/11-coupled GPCR — phospholipase C, inositol trisphosphate, calcium, protein kinase C, then release of stored LH and FSH. The mammalian type I GnRH receptor is unique among GPCRs in having no C-terminal cytoplasmic tail, which is the domain GRKs normally phosphorylate to recruit arrestin. It therefore desensitizes unusually slowly to a pulse — and that is precisely what a receptor designed to read an hour-and-a-half rhythm needs.
Frequency, not just presence, is the code. Pulse frequency differentially governs LH against FSH secretion: faster pulses favor LH, slower pulses favor FSH, and the mechanism by which one ligand at one receptor produces a differential effect on two hormones from the same cell is an open problem serious enough to be titled an enigma in its own review Lambalk 2023. The axis is frequency-modulated, and no dosing table can encode that.
And the failure mode, which is the most consequential sentence on this page. Continuous or too-frequent GnRH receptor stimulation eventually uncouples and downregulates the receptor, and gonadotropin output collapses. This is not a theoretical risk; it is the licensed mechanism of an entire drug class. Leuprolide and the other long-acting GnRH agonists are used to suppress the axis for prostate cancer, endometriosis and precocious puberty, and they work by being GnRH that never goes away. A gonadorelin schedule that drifts toward continuous delivery does not produce a weaker version of the intended effect. It produces the opposite effect.
Cell, rodent, human — and where it stops
Step one, receptor and axis: settled, and the pulse-frequency question is still open at the top of it Lambalk 2023.
Step two, the human genetics that prove the pathway is necessary. Loss-of-function variants in the GnRH receptor cause hypogonadotropic hypogonadism Fanis 2023. That is the strongest form of evidence a mechanism can have: break the receptor in a person and the axis does not run. It is also the evidence that defines who a GnRH agonist cannot help — if the defect is the receptor, no amount of ligand fixes it.
Step three, humans, therapeutically, and the delivery is the treatment. Congenital hypogonadotropic hypogonadism in male patients is treated by restoring the axis Lee 2022, and where pulsatile GnRH is used it requires a programmable pump delivering a bolus every 60 to 120 minutes. The pump is not a convenience. It is the drug. The alternative routes — gonadotropins given directly, hCG with or without FSH — bypass the pituitary altogether and are used precisely because reproducing a physiological pulse pattern is hard.
Step four, the use that is actually common: diagnosis. A GnRH stimulation test asks whether a pituitary can respond at all. The comparison between the triptorelin stimulation test and the gonadorelin stimulation test for diagnosing central precocious puberty has been examined directly Seo 2025. Diagnostically this molecule is a probe, and a probe is used once — which is a completely different exposure from a chronic protocol.
Step five, the mirror image, which clarifies the pharmacology. GnRH antagonists block the receptor competitively and suppress gonadotropins immediately, with no initial surge; the difference between agonist and antagonist effects on ovarian steroid secretion has been measured in humans Garcia-Velasco 2001, and the antagonist's own pharmacokinetics are characterized Duijkers 1998. Agonist and antagonist converge on the same end state by opposite routes, and the agonist gets there through an initial flare that the antagonist does not have.
Where the chain breaks. (1) The therapeutic evidence is in congenital hypogonadotropic hypogonadism Lee 2022 — a population whose axis has never run — and not in men with a suppressed axis from exogenous androgen. (2) The pump protocols are specialist, monitored and adjusted; nothing outside that setting reproduces them. (3) The frequency question is unresolved even in the specialist literature Lambalk 2023, so an optimal pattern cannot be stated. (4) Testicular responsiveness after prolonged suppression is a separate variable from pituitary responsiveness, and a GnRH agonist only addresses the second.
What would have to be true, and how you would know it was not
Three predictions. The first two are the axis working, and the third is the one that detects the opposite happening.
1. If the pituitary is responding, gonadotropins rise within minutes and the test is a single morning. LH/FSH measured at baseline and again shortly after a stimulus is the classical response test, and it is what the diagnostic literature is built on Seo 2025. A flat gonadotropin response to a stimulus is informative in itself: it points at the pituitary or the receptor Fanis 2023 rather than at the testis, and it means no delivery schedule will help.
2. The downstream read-out is the gonad, and it lags. Total testosterone and free testosterone in men, estradiol in women, at baseline and at 8 to 12 weeks. The lag is real — gonadotropins act on cells that must be recruited and restarted — so a 4-week judgment is premature. SHBG belongs in the same draw because total testosterone without it is uninterpretable when binding protein is shifting.
3. The falsification test, and it is the one that matters most. The mechanism predicts that too much, too often, or too continuous suppresses the axis rather than stimulating it. So the specific falsifying observation is: LH/FSH and testosterone that rise initially and then fall below baseline on an unchanged schedule. That pattern is receptor downregulation and it is the documented mechanism of an entire licensed drug class. It looks like the compound stopping working, and the correct response is to stop, not to dose more often. Measuring at baseline, 6 weeks and 12 weeks is what makes the difference between those two interpretations visible.
What nobody has tested yet
Four things nobody has established for the way this compound is actually used.
Nobody has published a pulse-frequency study in men with an androgen-suppressed axis. The frequency code is unresolved even in physiology Lambalk 2023, and the therapeutic protocols come from congenital deficiency Lee 2022. A dose-and-interval ranging study in the population that actually uses this compound has never been run, which means every schedule in circulation is borrowed from a different disease.
Nobody has compared gonadorelin against hCG head to head for testicular preservation. hCG acts at the LH receptor on the Leydig cell directly; gonadorelin acts on the pituitary and depends on the pituitary working. Those are different mechanisms with different failure modes, and a randomized comparison with intratesticular testosterone and semen parameters as endpoints does not exist.
Nobody has measured how fast the receptor recovers. If a schedule has downregulated the receptor, how long off-drug is needed before responsiveness returns is a straightforward stimulation-test study at intervals after discontinuation. It has not been published, and it is the question anybody who has over-dosed this compound most needs answered.
Nobody has tested subcutaneous bolus dosing against pump delivery. The specialist protocols use pumps. Most real-world use is intermittent injections hours apart. Whether a bolus every twelve hours reads to the receptor as a pulse or as a plateau is the single question on which the whole practice turns, and nobody has measured it with gonadotropin sampling.
Gonadorelin — its own safety story, not its class's
Gonadorelin's specific risk is not toxicity. It is that the same molecule produces opposite endocrine outcomes depending on how it is delivered, and the class block above cannot express that.
The dominant risk is axis suppression from over-frequent dosing. Continuous receptor occupancy downregulates the GnRH receptor and shuts gonadotropin output down. This is the licensed mechanism of GnRH agonist therapy for prostate cancer and endometriosis. A schedule that is too frequent does not under-deliver a benefit; it delivers medical castration, and it does so gradually enough that the person may interpret the falling testosterone as the compound losing potency.
The initial flare is real and is a specific hazard in one situation. Agonist exposure raises gonadotropins and sex steroids before it suppresses them Garcia-Velasco 2001. In anyone with a hormone-sensitive malignancy, that transient rise is the reason GnRH agonists are begun under specialist supervision, and it is why antagonists exist as an alternative.
Hypersensitivity and injection-site reactions are the ordinary risks of any injected peptide and are not the interesting ones here.
The population question. Everything known therapeutically is from congenital hypogonadotropic hypogonadism Lee 2022 and from diagnostic testing Seo 2025. Nobody has studied this molecule as a chronic adjunct in men on exogenous androgen, which is overwhelmingly how it is used, and the absence of that evidence is the honest headline.
What this page will not do. Print a dose or an interval. The interval is the active variable, the optimal interval is unknown even in specialist practice Lambalk 2023, and getting it wrong in one direction produces the opposite of the intended effect.
Sources read for this page
- Lambalk CB, et al. The enigma of the gonadotropin-releasing hormone pulse frequency governing individual secretion of luteinizing hormone and follicle-stimulating hormone. F&S Reports 2023 · PMID 37223768
- Fanis P, et al. Gonadotropin-Releasing Hormone Receptor (GnRHR) and Hypogonadotropic Hypogonadism. International Journal of Molecular Sciences 2023 · PMID 37958948
- Lee HS, et al. Treatment of congenital hypogonadotropic hypogonadism in male patients. Annals of Pediatric Endocrinology and Metabolism 2022 · PMID 36203268
Gonadorelin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These act on the top of the reproductive axis, and which direction they push depends on how they are given. hCG and gonadorelin stimulate; kisspeptin stimulates upstream of GnRH. Continuous GnRH agonism (triptorelin) paradoxically SUPPRESSES after an initial flare, because sustained signaling desensitizes the receptor. Cetrorelix is a straightforward antagonist and suppresses immediately.
- The predicted harm follows the direction: stimulation raises testosterone and estradiol together, so aromatization-driven effects arrive with it. Suppression produces a hypogonadal state — low libido, fatigue, mood change, and bone loss if prolonged.
- The initial FLARE on a GnRH agonist is the specific thing to know about: hormones rise sharply before they fall, and symptoms can transiently worsen.
What has actually been reported
- hCG is well characterized in fertility medicine — gynecomastia and fluid retention from the estradiol rise are the common complaints.
- GnRH agonist flare is documented and clinically managed in oncology with an antiandrogen during the first weeks.
How to reduce the risk
Same mechanism as the prediction.
- If using hCG alongside an androgen to preserve testicular function, lower and more frequent beats large and infrequent — the estradiol spike tracks the dose size.
- Anything suppressing the axis for more than a few months needs a bone density conversation, not just a hormone panel.
What it does to your bloodwork
A fact about the assay.
- LH and FSH, total and free testosterone, sensitive estradiol (these raise it more than people expect), and a semen analysis if fertility is the reason you are running it.
Don't run this if
- You have a hormone-sensitive cancer, unless this is being directed by an oncologist — in which case it is their protocol, not one to self-manage.
The honest unknown
- Kisspeptin analogs are early in human study. The axis effect is real and well demonstrated acutely; the consequences of repeated long-term use are not established.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Gonadorelin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Gonadorelin moves on your bloodwork
Expected direction, not a measured one.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Hematocrit and hemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatization converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Gonadorelin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Gonadorelin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| LH & FSH | The axis you're trying to restart |
| Total Testosterone | Whether the restart is working |
| Estradiol, Sensitive (LC/MS-MS) | Rises alongside testosterone and drives most symptoms |
| SHBG (Sex Hormone-Binding Globulin) | Determines how much of the recovery is actually usable |
The Post-Cycle / Recovery & Fertility panel covers these in one order — 9 markers, $184.50 with the discount applied.
Check results you already have → · All 103 markers A–Z
Gonadorelin — frequently asked questions
What is Gonadorelin?
Gonadorelin (GnRH) is a hormonal & sexual research compound. Synthetic GnRH — stimulates the pituitary to release LH/FSH, keeping the testicular axis active (the HCG alternative that works upstream).
Is the full Gonadorelin protocol on this page?
The reported research dose is on this page, along with how Gonadorelin works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Gonadorelin?
Gonadorelin has an approximate half-life of ~2-4 min, which is part of what determines how often it's dosed.
What's the evidence behind Gonadorelin?
Current evidence level: Human (established). Gonadorelin is offered for research purposes only and is not an approved medicine.
Gonadorelin inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Gonadorelin is used for
Gonadorelin appears under 3 goals in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
Gonadorelin is the upstream arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.